X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).
Lead Product(s): Fecal Microbiota Spores Live-brpk
Therapeutic Area: Infections and Infectious Diseases Product Name: Vowst
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nestle Health Sciences SA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
The agreement aimed to jointly commercialize Vowst (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibiotic treatment for recurrent CDI, following its FDA Approval.
Lead Product(s): Fecal Microbiota Spores Live-brpk
Therapeutic Area: Infections and Infectious Diseases Product Name: Vowst
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nestle Health Sciences SA
Deal Size: $525 million Upfront Cash: $175 million
Deal Type: Agreement May 30, 2023
Details:
The financing will support the commercial launch of Vowst, the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibacterial treatment for recurrent CDI and to fund company's pipeline development.
Lead Product(s): Fecal Microbiota Spores Live-brpk
Therapeutic Area: Infections and Infectious Diseases Product Name: Vowst
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Oaktree Capital Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 27, 2023
Details:
Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).
Lead Product(s): Fecal Microbiota Spores Live-brpk
Therapeutic Area: Infections and Infectious Diseases Product Name: Vowst
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nestle Health Sciences SA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
SER-109 is an oral microbiome therapeutic candidate consisting consortium of highly purified Firmicutes spores. It is designed to prevent further recurrences of CDI by modulating the disrupted microbiome to a state that resists C. difficile colonization and growth.
Lead Product(s): Firmicute Species Bacterial Spores
Therapeutic Area: Infections and Infectious Diseases Product Name: SER-109
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
SER-155 composition aims to decrease the colonization and abundance of bacterial pathogens, and to enhance epithelial barrier integrity in the GI tract to both reduce the likelihood of pathogen translocation and decrease the incidence of bloodstream infections.
Lead Product(s): SER-155,Vancomycin Hydrochloride
Therapeutic Area: Immunology Product Name: SER-155
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
SER-109 (Firmicute Species Bacterial Spores) is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in a healthy microbiome.
Lead Product(s): Firmicute Species Bacterial Spores
Therapeutic Area: Infections and Infectious Diseases Product Name: SER-109
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in a healthy microbiome.
Lead Product(s): Firmicute Species Bacterial Spores
Therapeutic Area: Infections and Infectious Diseases Product Name: SER-109
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
Clinical and preclinical data for SER-109, (Firmicute Species Bacterial Spores) support Seres’ development of microbiome therapeutics to reduce the incidence of antibiotic-resistant bacterial infections.
Lead Product(s): Firmicute Species Bacterial Spores
Therapeutic Area: Infections and Infectious Diseases Product Name: SER-109
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in a healthy microbiome.
Lead Product(s): SER-109
Therapeutic Area: Infections and Infectious Diseases Product Name: SER-109
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
